6,960 Shares in Cencora, Inc. $COR Acquired by Global X Japan Co. Ltd.

Key Points

• Global X Japan Co. Ltd. acquired a new stake of 6,960 shares in Cencora during the fourth quarter, valued at approximately $2.35 million.
• CEO Robert P. Mauch sold 5,096 shares on January 20 for about $1.81 million, cutting his stake by 7.1%; insiders now own just 0.38% of the company while institutional investors hold 97.52%.
• Cencora posted Q results with EPS $4.08 (beat by $0.04) and revenue of $85.93 billion (slightly below estimates) with revenue up 5.5% year-over-year, and Wall Street’s consensus rating is a Moderate Buy with an average target of $403.17.

Global X Japan Co. Ltd. acquired a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,960 shares of the company's stock, valued at approximately $2,351,000.

Other institutional investors have also recently added to or reduced their stakes in the company. IAG Wealth Partners LLC bought a new stake in Cencora in the third quarter valued at $30,000. Cloud Capital Management LLC bought a new position in shares of Cencora during the third quarter worth about $31,000. Caitlin John LLC bought a new position in shares of Cencora during the third quarter worth about $31,000. Harbor Investment Advisory LLC acquired a new stake in shares of Cencora in the 4th quarter worth about $35,000. Finally, Vermillion & White Wealth Management Group LLC lifted its position in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company's stock valued at $31,000 after purchasing an additional 43 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company's stock, valued at $23,669,713.98. This represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company's stock.

Cencora Trading Down 2.2%

Cencora stock opened at $318.00 on Friday. The company's fifty day simple moving average is $352.91 and its 200-day simple moving average is $340.41. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12 month low of $267.40 and a 12 month high of $377.54. The stock has a market cap of $61.86 billion, a P/E ratio of 38.22, a P/E/G ratio of 1.51 and a beta of 0.68.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period last year, the company earned $3.73 earnings per share. The business's revenue was up 5.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora's dividend payout ratio (DPR) is currently 28.85%.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. Wells Fargo & Company upped their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Bank of America decreased their price objective on Cencora from $380.00 to $360.00 and set a "neutral" rating for the company in a report on Monday, January 5th. Morgan Stanley set a $380.00 target price on Cencora in a research report on Tuesday, March 17th. Wall Street Zen downgraded Cencora from a "buy" rating to a "hold" rating in a research note on Friday, November 28th. Finally, Jefferies Financial Group upgraded Cencora from an "underperform" rating to a "buy" rating in a research report on Thursday, January 22nd. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $403.17.

Cencora Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.